53rd week of 2009 patent applcation highlights part 58 |
Patent application number | Title | Published |
20090325881 | MODIFIED FACTOR VIII - Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes. | 2009-12-31 |
20090325882 | CHAPERONIN 10 MODULATION OF TOLL-LIKE RECEPTOR-INDUCIBLE CYTOKINE AND CHEMOKINE SECRETION - Methods of use of Chaperonin 10 (Cpn10) are provided for regulating Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. Cpn10 negatively regulates Toll-like receptor agonist-induced pro-inflammatory cytokine and chemokine secretion, examples being IL-6 and RANTES, respectively. Cpn10 positively regulates Toll-like receptor agonist-induced anti-inflammatory cytokine and chemokine secretion, an example being IL-10. These immunoregulatory activities of Cpn10 may be useful in the treatment of diseases, disorders and conditions resulting from excessive pro-inflammatory cytokine and chemokine secretion. This invention also relates to producing, designing and/or screening Cpn10 agonists and antagonists according to their ability to regulate Toll-like receptor signaling and/or Toll-like receptor inducible immunomodulator secretion. | 2009-12-31 |
20090325883 | Peptides Which Interact with Anti-Apoptotic Members of the BCL-2 Protein Family, and Uses - The invention lies within the field of seeking out and identifying new peptides which interact with anti-apoptotic members of the Bcl-2 protein family, by means of the two-hybrid system. | 2009-12-31 |
20090325884 | Method for Detecting Autoantibodies Formed in Rheumatoid Arthritis - Autoantibodies reacting against citrullinated peptides derived from C-telopeptides of type I and type II collagens are found in patients with rheumatoid arthritis. They detect sequences —YYXA from α1 or —FYXA from α2 chain of type I collagen or —YMXA from α1 chain of type II collagen, where X is citrulline. The antibodies are different from anti-filaggrin antibodies. The peptides of the invention can be used in diagnosis of rheumatoid arthritis. Oral administration of citrullinated peptides can induce tolerance and lead to the treatment of rheumatoid arthritis. | 2009-12-31 |
20090325885 | COMPOSITION FOR ACCELERATION OF TYPE I COLLAGEN PRODUCTION - It is an object of the present invention to provide a composition for promoting the production of type I collagen by human skin fibroblasts, and the present invention relates to a composition for promoting type I collagen production containing silybin and a peptide that promotes collagen production (peptide having an amino acid sequence of Gly-Pro-Hyp, Gly-His-Lys, Lys-Thr-Thr-Lys-Ser or Gly-Glu-Pro-Arg). | 2009-12-31 |
20090325886 | WT1 MODIFIED PEPTIDE - The present invention discloses a cancer antigen peptide comprising the following amino acid sequence: Cys Tyr Thr Trp Asn Gln Met Asn Leu (Sequence ID No. 3), a cancer vaccine having this for its active ingredient, and a DNA vaccine having for its active ingredient DNA that codes for this peptide. | 2009-12-31 |
20090325887 | PEPTIDES AND REGULATION OF CALCIUM CHANNELS - Calcium channels can be regulated by natural gamma proteins. Herein we disclose embodiments of compositions and methods, particularly involving short peptides which are capable of regulating calcium channel function. Certain short peptides which can inhibit calcium current have structural features from the first transmembrane domain of gamma6 such as a GxxxA motif and adjoining aliphatic residues. In embodiments the peptide compositions and methods are capable of selective efficacy for low voltage-activated calcium channels, such as LVA channel Cav3.1, versus high voltage-activated channels. | 2009-12-31 |
20090325888 | Peptides having a health benefit and compositions comprising them - The present invention provides the tripeptide MAP and/or the tripeptide ITP and/or salts thereof for use as a health benefit agent, especially in functional food products. The tripeptides have particular application in the areas of the prevention of obesity or body weight control and cardiovascular health maintenance, especially the inhibition of angiotensin-converting enzyme and the control of blood cholesterol levels. Functional Food products comprising these tripeptides and having health benefits in these areas, and a process for making these products, are also provided. The tripeptides can be conveniently incorporated into food products to provide the aforementioned health benefits to the consumer thereof. | 2009-12-31 |
20090325889 | HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR - The present invention provides novel compounds which mimic peptides with a C-terminal penultimate proline, such compounds being useful as protease inhibitors, particularly as inhibitors of serine proteases, and more particularly as inhibitors of the NS3 serine protease from hepatitis C. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment. | 2009-12-31 |
20090325890 | USE OF GALACTOSE C-GLYCOSIDE DERIVATIVES AS PROTECTIVE AGENT AND/OR GAMA DELTA T LYMPHOCYTE ACTIVATOR - The present invention relates to the use of at least one galactose-derived C-glycoside of general formula (I): | 2009-12-31 |
20090325891 | Cartilage regeneration-promoting agent - An object of the present invention is to provide an excellent cartilage regeneration-promoting agent that can promote regeneration of cartilage efficiently and is highly safe, and a medicine and a food that utilizes the cartilage regeneration-promoting agent. Thus, the present invention relates to a cartilage regeneration-promoting agent that includes at least one of hydroxytyrosol and a precursor of hydroxytyrosol, and to a medicine and a food that includes the cartilage regeneration-promoting agent. | 2009-12-31 |
20090325892 | Synergistic pesticidal mixtures - Synergistic pesticidal mixtures are provided. | 2009-12-31 |
20090325893 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME - Methods are provided for using doxorubicin active agents in which reduced host toxicity is observed. Aspects of the methods including administering to a subject an effective amount of a doxorubicin active agent in conjunction with a doxorubicin toxicity-reducing adjuvant, e.g., a nitrone compound, or a nitrone compound in combination with a bisdioxopiperazine compound. Also provided are compositions for use in practicing the subject methods. The methods and compositions find use in a variety of different applications, including in the treatment of a variety of different disease conditions. | 2009-12-31 |
20090325894 | TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES - The present invention provides aminoside tetracyclic anthraquinones represented by formula (I) or formula (II), wherein the peptides are introduced to connect tetracyclic anthraquinones and fatty acid saturated or unsaturated in order to make the anticancer agents to be absorbed and released selectively; meanwhile some water-solubility groups are also introduced into the branched chain, aminosaccharide and tetracyclic moiety of the compounds to improve the water-solubility. The present invention also provides the preparative method and the use thereof as pharmaceutically active components for treating the diseases cured by aminoside tetracyclic anthraquinone, for example cancer, such as intestines, liver, gastric, breast, lung, ovary, prostate, brain glioma, lymph, skin, pigment, thyroid gland, multiple bone marrow cancer and leukemia. | 2009-12-31 |
20090325895 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE - The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier. | 2009-12-31 |
20090325896 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS - Disclosed are novel compounds that are partial and full A | 2009-12-31 |
20090325897 | DESIGNER THERAPY OF PANCREATIC TUMORS - Chemotherapeutic and Radiation sensitizing agents which target tumor cells, specifically, based on the elevation of enzyme pathways, provide highly selective drug therapy. These agents are combined with modulating doses of cytidine deaminase inhibitors to increase selectivity. Furthermore, high doses of these cytidine deaminase inhibitors have the potential of counteracting the aggressive and metastatic characteristics of pancreatic tumors. For tumors with high levels of cytidine deaminase, such as pancreatic tumors, this elevation provides a therapeutic approach with prodrugs that require deamination for their activation. For tumors with high levels of uridine/cytidine kinase, a different class of pyrimidine analogs can be activated selectively in tumors for a therapeutic advantage. | 2009-12-31 |
20090325898 | SKIN MATERIAL FOR EXTERNAL USE AND ANTIPRUTIRIC AGENT FOR EXTERNAL USE AND WRINKLE-INSTRUMENT USING THE SAME - A skin composition for external use containing an acidic composition (A) which contains an alginate(s), at least one of weak acid selected from among phosphoric acid-type weak acids and ethylenediaminetetraacetic acid-type weak acids, and water; and a solidifying/gelling agent (B) containing a calcium salt(s) which is to be supplied to the acidic composition (A) sticking to the skin surface. In some cases, the skin composition for external use further includes an absorbent to be impregnated with the acidic composition (A). | 2009-12-31 |
20090325899 | MEDICAL COMPOSITION FOR PROTUBERANCE OF EPITHELIUM - A medical composition for protuberance of epithelium, which comprises a solution comprising a polysaccharide or a medically acceptable salt thereof, wherein the solution has a viscosity of: (1) from 50 to 500 mPa·s at a shear rate of from 7.7 to 10.0 s | 2009-12-31 |
20090325900 | FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF - The present invention provides a compound useful as an agent for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides a fused heterocyclic derivative represented by the following general formula (I), a pharmaceutical composition containing the same, a medicinal use thereof and the like. In the formula (I), ring A represents 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; R | 2009-12-31 |
20090325901 | IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS - The present invention relates to compounds of formula I or II: —wherein R is an alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group, that may be substituted or unsubstituted, and that optionally includes at least one heteroatom in its carbon skeleton; R | 2009-12-31 |
20090325902 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF - Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. | 2009-12-31 |
20090325903 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2009-12-31 |
20090325904 | MALEIC ACID MONOSALT OF ANTIVIRAL AGENT AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - The present invention relates to 3-[({1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl}oxy)methyl]-8,8-dimethyl-3,7-dioxo-2,4,6-trioxa-3λ5-phosphanon-1-yl-pivalate maleic acid monosalt, and pharmaceutical composition containing the same. | 2009-12-31 |
20090325905 | METHOD FOR TREATING DISEASES ASSOCIATED WITH ALTERATIONS IN CELLULAR INTEGRITY USING RHO KINASE INHIBITOR COMPOUNDS - This invention is directed to methods of preventing or treating diseases or conditions associated with alterations in cellular integrity including alterations in endothelial permeability, excessive cell proliferation or tissue remodeling. Particularly, this invention is directed to methods of treating diabetic nephropathy, malaria, or cancer. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel rho kinase inhibitor compound to treat the disease. | 2009-12-31 |
20090325906 | Methods and compositions for therapeutic treatment - Methods and compositions are described for the modulation of hyperglycemia and/or one or more symptoms of hyperglycemia. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of calcineurin inhibitors out of a physiological compartment and into an external environment. In particular, the methods and compositions disclosed herein provide for the increase of efflux transporter activity to increase the efflux of calcineurin inhibitor from physiological compartments. | 2009-12-31 |
20090325907 | AMINO PHOSPHATE DERIVATIVE AND S1P RECEPTOR MODULATOR HAVING SAME AS AN ACTIVE INGREDIENT - To provide an amino phosphate derivative having an excellent sphingosine-1-phosphate (S1P) receptor modulatory action. | 2009-12-31 |
20090325908 | 9-SUBSTITUTED MINOCYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 2009-12-31 |
20090325909 | Suppression of HIV replication and prevention and treatment of HIV - The invention provides a new and effective treatment for human immunodeficiency diseases, particularly for HIV-infected individuals. The treatment utilizes tetracycline analogs, particularly minocycline, in amounts that are effective to prevent HIV replication both the central nervous system and in peripheral blood. | 2009-12-31 |
20090325910 | COMPOSITIONS AND METHODS FOR TRANQUILIZING HEART MUSCLE - A pharmaceutical composition for tranquilizing cardiomyocytes present in heart muscle in a subject diagnosed with a cardiac overload disease comprises a therapeutically effective amount of a Vitamin D | 2009-12-31 |
20090325911 | Use of Androgens for the Treatment of Parkinson's Disease - The invention generally provides therapeutic and prophylactic methods relating to the use of androgens for the treatment of Parkinson's disease or other neurodegenerative diseases. In addition, the invention provides related methods of screening for compounds for the treatment of Parkinson's disease. | 2009-12-31 |
20090325912 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS - Compounds of formula I | 2009-12-31 |
20090325913 | Treatment of pain using satraplatin - The instant invention relates to methods using satraplatin, packaged-pharmaceutical-products that include satraplatin and uses of satraplatin to prepare pharmaceutical compositions for the treatment of pain associated with metastatic hormone refractory prostate cancer. | 2009-12-31 |
20090325914 | Administration of fluocinolone acetonide, tretinoin and hydroquinone cream in melasma maintenance therapy - Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence. | 2009-12-31 |
20090325915 | Crystalline Levosalbutamol Sulphate and Polymorphic Forms Thereof - The invention provides three polymorphic forms of crystalline levosalbutamol sulphate designated herein as Forms I, II and III. | 2009-12-31 |
20090325916 | 5-ARYL INDAN-1-ONE AND ANALOGS USEFUL AS PROGESTERONE RECEPTOR MODULATORS - Compounds of formula I or II and pharmaceutical compositions and kits containing these compounds are provided. Also provided are methods of inducing contraception, providing hormone replacement therapy, treating cycle-related symptoms, or treating or preventing benign or malignant neoplastic disease using the compounds of formula I, formula II, or formula III. | 2009-12-31 |
20090325917 | Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate - A stable aqueous pharmaceutical composition comprising anhydrous mometasone furoate and a pharmaceutically acceptable carrier. | 2009-12-31 |
20090325918 | Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action - Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone have fewer effects mediated by gonadal steroid receptors relative to effect mediated by minteralocorticoid progesterone receptors, compared to the stereoisomerically unpurified form of the compound. These optically active compounds can be useful for obtaining reduction in moderate essential hypertension and it the treatment of congestive heart failure in humans with minimized undesirable side effects such as gynecomastia, tender breast enlargement and menstrual irregularities in women, and loss of libido in men. | 2009-12-31 |
20090325919 | METHOD OF PREPARATION OF A SOLUBLE FORMULATION OF WATER-INSOLUBLE PENTACYCLIC AND TETRACYCLIC TERPENOIDS, A SOLUBLE FORMULATION OF A PENTACYCLIC OR TETRACYCLIC TERPENOID AND A PHARMACEUTICAL COMPOSITION CONTAINING THIS SOLUBLE FORMULATION - The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is —OC—R—COOH, substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is —OC—R—COOH, quarternary ammonium substituents of general formula Xb bound to the carboxy group of the terpenoid, wherein Xb is —(CH2)nN+R3Y—, quarternary ammonium substituents of general formula Xc bound to the carboxy group of the terpenoid, wherein Xc je —(CH2)nR+Y—, substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents —R—COOH, glycosylic substituents Xe bound by alpha or beta glycosidic bond to the hydroxy group or to the carboxy group of the terpenoid, wherein Xe is selected from the group comprising glucosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof, and subsequently, the prepared derivative is dissolved in the solution containing water, a cyclodextrin and optionally pharmaceutically acceptable auxiliary substances, forming an inclusion derivative with the cyclodextrin. Object of the invention is further a soluble formulation of a pentacyclic or tetracyclic triterpenoid, containing an inclusion complex of the derivatized pentacyclic or tetracyclic terpenoid with a cyclodextrin, and optionally water and pharmaceutically acceptable auxiliary substances and further a pharmaceutical composition containing the soluble formulation. | 2009-12-31 |
20090325920 | METHODS FOR THE TREATMENT OF A TRAUMATIC CENTRAL NERVOUS SYSTEM INJURY - Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject. | 2009-12-31 |
20090325921 | METHOD OF IMPROVING THE OVERALL HEALTH OF A PATIENT WITH USE OF A TRANSDERMAL DHEA CREAM AND/OR DHEA SULFATE CREAM - A method is described herein for improving the overall health of a patient by providing a topical DHEA cream and applying the topical DHEA cream to at least one part of a body. In another embodiment, the topical DHEA cream is mixed with a moisturizing lotion and the resulting DHEA/lotion mixture is applied to at least one part of a body. In yet another embodiment, the topical DHEA cream is mixed with a sulfate lotion and the resulting DHEA/sulfate lotion combination is applied to at least one part of a body. | 2009-12-31 |
20090325922 | TURFGRASS FUNGICIDE FORMULATION WITH PIGMENT - Oil-in-water fungicidal formulations are prepared having pigment dispersed therein, the pigment being stable within the oil-in-water emulsion as a result of the addition of suitable silicone surfactants and suitable emulsifiers. The formulations can be prepared either as a 2-pack formulation or as a single formulation. In the case of the single formulation polyethylene glycol is also added. In either case, the formulations show a synergistic effect through the addition of the pigment, the resulting formulations having an increased efficacy. Further, the formulations show a synergistic effect when mixed with conventional chemical fungicides, both being added in reduced amounts compared to recommended rates. | 2009-12-31 |
20090325923 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES - The present invention relates to the use of an inhibitor of the formation of nicotinamide adenyl dinucleotide for the preparation of a medicament used in the treatment of inflammatory diseases such as rheumatoid arthritis and endotoxemia. | 2009-12-31 |
20090325924 | GPCR Agonists - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. | 2009-12-31 |
20090325925 | Thiophenes and uses thereof - This invention provides thiophene compounds of formula I: | 2009-12-31 |
20090325926 | PYRROLO[3,2-D] PYRIMIDINES AS DPP-IV INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS - The present invention relates to substituted pyrrolo[3,2-d]pyrimidines of formula (I), wherein R1 and R2 are defined as in claim | 2009-12-31 |
20090325927 | Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor - Benzofuro- and benzothienopyrimidine compounds are described, which are useful as H | 2009-12-31 |
20090325928 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors - Compounds of the formula | 2009-12-31 |
20090325929 | QUATERNARY AMMONIUM SALT COMPOUNDS OF SPIROCYCLOPIPERAZINES, PREPARATION METHODS AND USES THEREOF - Compounds represented by general formula (I), their stereoisomers, tautomers, derivatives, prodrugs or pharmaceutically acceptable salts, and their preparation methods or uses for the manufacture of a medicament of analgesics. In which R | 2009-12-31 |
20090325930 | SELECTIVE ESTROGEN RECEPTOR MODULATOR - The present invention provides a compound represented by the following formula (I); | 2009-12-31 |
20090325931 | USE OF CDK INHIBITORS FOR THE TREATMENT OF GRANULOCYTE MEDIATED DISORDERS - Described herein is the use of CDK inhibitors such as roscovitine for inducing apoptosis of granulocytes, for example neutrophils. Their use for treating inflammatory diseases is also provided. | 2009-12-31 |
20090325932 | 4-PIPERIDYLBENZAMIDES AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS - A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11 βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g the metabolic syndrome. | 2009-12-31 |
20090325933 | Pyrimidinone Derivatives and Their Use as a Drug - The present application relates to new pyrimidinone derivatives. These products have a good affinity for certain sub-types of cannabinoid receptors, especially the CB2 receptors. They are particularly attractive for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a drug. | 2009-12-31 |
20090325934 | METHOD FOR TREATING NEUROLOGICAL AND NEUROPATHIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS - This invention is directed to methods of preventing or treating neurological or neuropathic diseases or conditions associated with excessive inflammation, neurodegeneration, neuro-remodeling, and axonal/neurite retraction. Particularly, this invention relates to methods treating neurological or neuropathic diseases such as cerebral ischemia, stroke, neuropathic pain, spinal cord injury, Alzheimer's disease, and multiple sclerosis, using novel rho kinase inhibitor compounds. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel rho kinase inhibitor compound to treat the disease. | 2009-12-31 |
20090325935 | GYRASE INHIBITORS AND USES THEREOF - The present invention relates to compounds that inhibit bacterial gyrase and/or Topo IV and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. | 2009-12-31 |
20090325936 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES - The present invention relates to compounds represented by Formula (I) and Formula (II): (I) (II) or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases. | 2009-12-31 |
20090325937 | Pyridazine Compounds as Glycogen Synthase Kinase 3 Inhibitors - Disclosed are pyridazine compounds of the formula I which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds: | 2009-12-31 |
20090325938 | CONTROLLED-RELEASE CNS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS - Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s). | 2009-12-31 |
20090325939 | 1H-INDAZOLES, BENZOTHIAZOLES, 1,2-BENZOISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND CHROMONES AND PREPARATION AND USES THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. | 2009-12-31 |
20090325940 | Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof - The present invention relates to substituted 1,2-ethylenediamines of general formula (I) | 2009-12-31 |
20090325941 | NOVEL 2-(2-HYDROXYPHENYL) BENZOTHIADIAZINES USEFUL FOR TREATING OBESITY AND DIABETES - The present invention relates to novel compounds that act as chemical uncouplers. Compounds of the invention are useful, inter alia, in the treatment, including prevention, of obesity, diabetes and a number of diseases or conditions associated therewith. | 2009-12-31 |
20090325942 | PHENOTHIAZIN DERIVATES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS PHARMACEUTICALS - The invention relates to compounds of the formula 1, | 2009-12-31 |
20090325943 | VETERINARY PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND INFLAMMATION - This invention relates to veterinary pharmaceutical compositions based on a combination of tramadol and meloxicam or carprofen for the treatment of pain and inflammation in animals. | 2009-12-31 |
20090325944 | Methods and Compositions for Modulating Glycosylation - The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for treating glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such as insulin resistance, nephropathy, microvascular damage, and endothelial dysfunction. The invention also relates in part to assays that are useful for identifying and testing candidate compounds for modulating glycosylation of proteins. | 2009-12-31 |
20090325945 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS - The present invention pertains to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5 b]pyridin-2-one compounds and analogs thereof, which, inter alia, inhibit RAF (e.g., B RAF) activity, inhibit cell proliferation, treat cancer, etc., and more particularly to compounds of the formulae: wherein: J is independently —O— or —NR | 2009-12-31 |
20090325946 | NOVEL PHENOLIC AND CATECHOLIC AMINES AND PRODRUGS THEREOF - The present invention relates to novel phenolic and catecholic amines of Formula I, to processes for their preparation, pharmaceutical compositions containing them, to their use in therapy and to their use in radiolabeled form as PET- or SPECT ligands. | 2009-12-31 |
20090325947 | NITRATE ESTERS OF PIPERIDINES - The application relates to novel nitrate ester derivatives of substituted piperidines of the general formula (I), wherein R | 2009-12-31 |
20090325948 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE - The present invention relates to compounds that are selective and/or potent inhibitors of UPPS. In addition to compounds which inhibit UPPS, the invention also provides pharmaceutical compositions comprising these compounds and methods of using these compounds for treating bacterial disease, such as bacterial infection. | 2009-12-31 |
20090325949 | 5 HT RECEPTOR MEDIATED NEUROGENESIS - The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells. | 2009-12-31 |
20090325950 | Benzoxazine derivatives and uses thereof - The present invention provides a compound of the formula: | 2009-12-31 |
20090325951 | THIENYL-AND FURANYL-ISOQUINOLINONES AND METHODS FOR USING THEM - The present invention relates to substituted thienyl- and furanyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates to processes for the preparation of substituted thienyl and furanyl-isoquinolinones and to their use in treating various diseases and disorders. | 2009-12-31 |
20090325952 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS - The invention provides a compound of formula (I) or a salt thereof: | 2009-12-31 |
20090325953 | P38 KINASE INHIBITING AGENTS - Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: | 2009-12-31 |
20090325954 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The invention concerns pyrimidine derivatives of Formula (I), wherein each of p, R | 2009-12-31 |
20090325955 | GYRASE INHIBITORS AND USES THEREOF - The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with one or more additional antibacterial agents and/or one or more additional therapeutic agents that increase the susceptibility of bacterial organisms to antibiotics. | 2009-12-31 |
20090325956 | Aromatic amine derivative and use thereof - The present invention provides a novel SCD inhibitor. An SCD inhibitor containing a compound represented by the formula [I] | 2009-12-31 |
20090325957 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS - A compound of formula (I) | 2009-12-31 |
20090325958 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS - This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease. | 2009-12-31 |
20090325959 | METHOD FOR TREATING OPHTHALMIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS - This invention is directed to methods of preventing or treating ocular diseases with inflammation, excessive cell proliferation, remodeling, neurite retraction, corneal neurodegeneration, excessive vaso-permeability and edema. Particularly, this invention relates to methods treating ocular diseases such as allergic conjunctivitis, corneal hyposensitivity, neurotrophic keratopathy, dry eye disease, proliferative vitreal retinopathy, macular edema, macular degeneration, and blepharitis, using novel Rho kinase inhibitor compounds. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel Rho kinase inhibitor compound to treat the disease. | 2009-12-31 |
20090325960 | METHOD FOR TREATING INFLAMMATORY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS - This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, edema and inflammation. Particularly, this invention is directed to methods of treating inflammatory diseases or conditions such as rheumatoid arthritis and inflammatory bowel disease. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a compound of a novel rho kinase inhibitor compound to treat the disease. | 2009-12-31 |
20090325961 | INDANE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF - Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): | 2009-12-31 |
20090325962 | TYROSINE DERIVATIVE - The compounds of the invention are inhibitors of alpha4 containing integrin-mediated binding to ligands such as VCAM-1 and MAdCAM. | 2009-12-31 |
20090325963 | Iontophoretic Delivery of Curcumin and Curcumin Analogs for the Treatment of Alzheimer's Disease - A method of delivering a curcuminoid to a patient, which includes iontophoretically delivering a charged curcuminoid across the skin of an Alzheimer's Disease patient. | 2009-12-31 |
20090325964 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression - The present teachings relate to piperazine metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators having Formula I: | 2009-12-31 |
20090325965 | BIOCIDAL COMPOSITIONS - Compositions of 1-(3-chloroallyl)-3,5,7-triaza-1-azonia-adamantane chloride, and an optional second biocide, in copolymers of ethylene oxide/propylene oxide are provided. The compositions exhibit good color and phase stability. | 2009-12-31 |
20090325966 | s-Triazine compounds, pharmaceutical compositions and method of using the same - Novel s-triazine compounds are disclosed that have a formula represented by the following: | 2009-12-31 |
20090325967 | ADENOSINE DERIVATIVES AS A2A RECEPTOR AGONISTS - A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U | 2009-12-31 |
20090325968 | Compositions Useful as Inhibitors of Protein Kinases - The present invention provides a compound of formula I: | 2009-12-31 |
20090325969 | METHOTREXATE ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME - Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions. | 2009-12-31 |
20090325970 | AZA-INDOLES AND RELATED COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ANTAGONIST BIOLOGICAL ACTIVITY - The present invention provides compounds are disclosed herein having the formula: | 2009-12-31 |
20090325971 | Pentacyclic Alkaloid Compounds and Methods of Use Thereof - The present invention relates to Pentacyclic Alkaloid Compounds, compositions comprising an effective amount of a Pentacyclic Alkaloid Compound and methods for treating or preventing cancer, a bacterial infection, a fungal infection, or a yeast infection, comprising administering to a subject in need thereof an effective amount of a Pentacyclic Alkaloid Compound. The present invention also relates to compounds and methods that are useful for making Cribrostatin IV. | 2009-12-31 |
20090325972 | NOVEL CINNAMALDEHYDE DERIVATIVES HAVING IMPROVED SOLUBILITY IN WATER, A METHOD FOR PREPARING THE SAME AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - Disclosed herein are a novel cinnamaldehyde compound represented by Chemical Formula 1 or pharmaceutically acceptable salts thereof. The cinnamaldehyde compound has improved solubility in water and has inhibitory effects on the growth of cancer cells because it induces cell cycle arrest and cell death. Also disclosed are a method of preparing the cinnamaldehyde compound and an anticancer composition including the compound of Chemical Formula 1. | 2009-12-31 |
20090325973 | FORMULATIONS CONTAINING PYRIDAZINE COMPOUNDS - The invention relates to chemical compounds, compositions and methods of making and using the same. In particular, the invention provides selected pyridazine compounds of the formula I | 2009-12-31 |
20090325974 | 1,5-DIPHENYLPYRAZOLES II AS HSP90 INHIBITORS - Novel 1,5-diphenylpyrazole derivatives of the formula (I) in which R | 2009-12-31 |
20090325975 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain - The present invention refers to the use of compounds active on the sigma receptor for the production of a medicament for the treatment of diabetes-associated pain. | 2009-12-31 |
20090325976 | PROSTACYCLIN DERIVATIVES - This invention relates to novel prostacyclin derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors. | 2009-12-31 |
20090325977 | CANCER COMBINATION THERAPY COMPRISING AZD2171 AND IMATINIB - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor or a leukaemia, which comprises the administration of AZD2171 in combination with imatinib; to a pharmaceutical composition comprising AZD2171 and imatinib; to a combination product comprising AZD2171 and imatinib for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and imatinib; to the use of AZD2171 and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation. | 2009-12-31 |
20090325978 | STABLE LYOPHILIZED PREPARATION - The present invention provides a lyophilized preparation that has excellent stability over time and excellent solubility when reconstituted, and that contains (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide. The present invention discloses a lyophilized preparation containing 1) (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide or a pharmaceutically acceptable salt thereof, 2) a pH regulator for adjusting a pH of the preparation to between 5 and 8, and 3) at least one of excipients selected from the groups consisting of sugars and sugar alcohols. | 2009-12-31 |
20090325979 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF - Disclosed are novel imidazolylalkylcarbonyl derivatives useful as calcium channel modulators and a preparation method of the same. Also disclosed is a method for the treatment of diseases by administering the above compounds based on their inhibitory activity against calcium channel. | 2009-12-31 |
20090325980 | PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS - The present invention is concerned with novel piperidine or piperazine substituted tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes. | 2009-12-31 |